MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoenfeld, J. R.
Right arrow Articles by Lowe, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoenfeld, J. R.
Right arrow Articles by Lowe, D. G.

Agonist selectivity for three species of natriuretic peptide receptor-A

JR Schoenfeld, P Sehl, C Quan, JP Burnier and DG Lowe

Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080.

We determined the nucleotide sequence of mouse natriuretic peptide receptor-A (NPR-A) cDNA and compared the revised deduced amino acid sequence with those of rat and human NPR-A. The ligand selectivity of these three receptor/guanylyl cyclases was examined by whole-cell stimulation of cGMP production. The 28-amino acid atrial natriuretic peptide (ANP) has only one difference among these three species, i.e., human Met-12 versus rat and mouse Ile-12. However, despite the nearly invariant ANP sequence among these species, ANP analogs have marked differences in ED50 values and maximal cGMP responses among the three receptors. With the natriuretic peptide analogs we tested, human NPR-A is less sensitive than rat or mouse NPR-A to changes in the 17-amino acid, disulfide-bonded ring of ANP and to the species differences in brain natriuretic peptide (BNP) but is more sensitive to deletions in the carboxyl tail of ANP. The ANP determinants of agonist potency have therefore changed for different species of NPR-A. This is reflected in the amino acid sequence divergence in the receptor extracellular domains and in the divergence and specificity of BNP among species. Our results suggest that the coevolution of NPR-A and BNP has thus been constrained within the context of the conserved ANP sequence.

Volume 47, Issue 1, pp. 172-180, 01/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
M. Parat, N. McNicoll, B. Wilkes, A. Fournier, and A. De Lean
Role of Extracellular Domain Dimerization in Agonist-Induced Activation of Natriuretic Peptide Receptor A
Mol. Pharmacol., February 1, 2008; 73(2): 431 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. J. Olson, B. Y. Ho, L. W. Cashdollar, and J. G. Drewett
Functionally Active Catalytic Domain Is Essential for Guanylyl Cyclase-Linked Receptor Mediated Inhibition of Human Aldosterone Synthesis
Mol. Pharmacol., November 1, 1998; 54(5): 761 - 769.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. E. Clemens, R. G. Almirez, K. A. Baudouin, R. P. Mischak, E. B. Grossbard, and A. A. Protter
Pharmacokinetics and Biological Actions of Subcutaneously Administered Human Brain Natriuretic Peptide
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 67 - 71.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics